Salvador VillÃ

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6744976/publications.pdf

Version: 2024-02-01

94269 123241 12,771 63 37 61 citations h-index g-index papers 63 63 63 15153 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Influence of glioblastoma contact with the subventricular zone on survival and recurrence patterns. Clinical and Translational Oncology, 2021, 23, 554-564.	1.2	14
2	Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. Annals of Oncology, 2021, 32, 171-182.	0.6	42
3	Primary extranodal lymphoma of the glands. Literature review and options for best practice in 2019. Critical Reviews in Oncology/Hematology, 2019, 135, 8-19.	2.0	8
4	Paraganglioma of the head and neck region, treated with radiation therapy, a Rare Cancer Network study. Head and Neck, 2019, 41, 1770-1776.	0.9	12
5	Recomendaciones de GESIDA/PETHEMA sobre el diagnóstico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana. Medicina ClÃnica, 2018, 151, 39.e1-39.e17.	0.3	5
6	Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience. Radiotherapy and Oncology, 2018, 127, 96-102.	0.3	23
7	Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). Radiotherapy and Oncology, 2018, 128, 260-265.	0.3	123
8	Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. Clinical and Translational Oncology, 2018, 20, 1529-1537.	1.2	0
9	Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines. Clinical and Translational Oncology, 2017, 19, 727-734.	1.2	7
10	Second re-irradiation for DIPG progression, re-considering "old strategies―with new approaches. Child's Nervous System, 2017, 33, 849-852.	0.6	14
11	ECOG or Karnofsky Performance Status to Assess Functionality in Glioblastoma Patients Among Different Observers. Journal of Molecular Biomarkers & Diagnosis, 2017, 01, .	0.4	O
12	Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma: A Rare Cancer Network study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 521-532.	0.7	12
13	Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). Clinical Cancer Research, 2016, 22, 4797-4806.	3.2	105
14	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. Journal of Neuro-Oncology, 2016, 127, 569-579.	1.4	40
15	Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. Journal of Clinical Oncology, 2016, 34, 1748-1756.	0.8	182
16	Localized prostate cancer treated with external beam radiation therapy: Long-term outcomes at a European comprehensive cancer centre. Reports of Practical Oncology and Radiotherapy, 2016, 21, 181-187.	0.3	12
17	Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Neuro-Oncology, 2015, 17, 588-595.	0.6	79
18	High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2015, 16, 320-327.	5.1	256

#	Article	IF	CITATIONS
19	Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 904-910.	0.4	52
20	Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force. Annals of Oncology, 2014, 25, 2134-2146.	0.6	90
21	History of the Rare Cancer Network and past Research. Rare Tumors, 2014, 6, 86-90.	0.3	7
22	Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation. Journal of Neuro-Oncology, 2014, 117, 77-84.	1.4	20
23	Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline. Clinical and Translational Oncology, 2014, 16, 436-446.	1.2	64
24	Radiation and concomitant chemotherapy for patients with glioblastoma multiforme. Chinese Journal of Cancer, 2014, 33, 25-31.	4.9	25
25	Quality assurance of radiotherapy in the ongoing EORTC 22042–26042 trial for atypical and malignant meningioma: results from the dummy runs and prospective individual case Reviews. Radiation Oncology, 2013, 8, 23.	1.2	26
26	A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results. Journal of Clinical Oncology, 2013, 31, 65-72.	0.8	559
27	Primary pineal tumors: outcome and prognostic factorsâ€"a study from the Rare Cancer Network (RCN). Clinical and Translational Oncology, 2012, 14, 827-834.	1.2	27
28	Evolution of care for patients with relapsed glioblastoma. Expert Review of Anticancer Therapy, 2011, 17, 1719-1729.	1.1	6
29	Validation of the new graded prognostic assessment scale for brain metastases: a multicenter prospective study. Radiation Oncology, 2011, 6, 23.	1.2	51
30	Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study. Journal of Clinical Oncology, 2011, 29, 134-141.	0.8	1,703
31	Phase II randomized study of preradiation treatment with temozolomide (TMZ) and bevacizumab (BEV) previous to TMZ plus radiation plus BEV versus the same treatment without BEV therapy in unresectable glioblastoma (GB): GENOM 009 Journal of Clinical Oncology, 2011, 29, e12519-e12519.	0.8	1
32	Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: A retrospective rare cancer network study. Critical Reviews in Oncology/Hematology, 2010, 74, 66-71.	2.0	13
33	The Results of Surgery, With or Without Radiotherapy, for Primary Spinal Myxopapillary Ependymoma: A Retrospective Study From the Rare Cancer Network. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1114-1120.	0.4	102
34	Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. European Journal of Cancer, 2009, 45, 2825-2834.	1.3	74
35	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, The, 2009, 10, 459-466.	5.1	6,451
36	Atypical and Malignant Meningioma: Outcome and Prognostic Factors in 119 Irradiated Patients. A Multicenter, Retrospective Study of the Rare Cancer Network. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1388-1393.	0.4	197

#	Article	IF	CITATIONS
37	Outcome after combined modality treatment for uterine papillary serous carcinoma: A study by the Rare Cancer Network (RCN). Gynecologic Oncology, 2008, 108, 298-305.	0.6	54
38	Translational research in glioblastoma multiforme: molecular criteria for patient selection. Future Oncology, 2008, 4, 219-228.	1.1	16
39	Stereotactic Radiation Therapy in Primary Optic Nerve Sheath Meningioma. Medical Radiology, 2008, , 105-127.	0.0	4
40	The impact of radiotherapy in the treatment of desmoid tumours. An international survey of 110 patients. A study of the Rare Cancer Network. Radiation Oncology, 2007, 2, 12.	1.2	79
41	Palliative treatment of Erdheim–Chester disease with radiotherapy: A Rare Cancer Network study. Radiotherapy and Oncology, 2006, 80, 323-326.	0.3	34
42	Fractionated stereotactic radiotherapy in the treatment of exclusive cavernous sinus meningioma: functional outcome, local control, and tolerance. World Neurosurgery, 2006, 65, 28-33.	1.3	77
43	Primary spinal epidural lymphoma: Patients' profile, outcome, and prognostic factors: A multicenter Rare Cancer Network study. International Journal of Radiation Oncology Biology Physics, 2006, 65, 817-823.	0.4	65
44	Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: A retrospective study from the Rare Cancer Network. International Journal of Radiation Oncology Biology Physics, 2006, 66, 179-186.	0.4	59
45	Intracranial retrograde dissemination in filum terminale myxopapillary ependymomas. Acta Neurochirurgica, 2006, 148, 343-346.	0.9	44
46	Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial. Journal of Clinical Oncology, 2006, 24, 2563-2569.	0.8	447
47	Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial. International Journal of Radiation Oncology Biology Physics, 2005, 61, 185-191.	0.4	200
48	Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas. Clinical Cancer Research, 2005, 11, 5167-5174.	3.2	181
49	The curative role of radiotherapy in adenocarcinoma of the prostate in patients under 55 years of age: A rare cancer network retrospective study. Radiotherapy and Oncology, 2005, 77, 286-289.	0.3	19
50	Risk-Adapted Androgen Deprivation and Escalated Three-Dimensional Conformal Radiotherapy for Prostate Cancer: Does Radiation Dose Influence Outcome of Patients Treated With Adjuvant Androgen Deprivation? A GICOR Study. Journal of Clinical Oncology, 2005, 23, 6561-6568.	0.8	64
51	Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. International Journal of Radiation Oncology Biology Physics, 2004, 59, 501-508.	0.4	100
52	Early improvements in vision after fractionated stereotactic radiotherapy for primary optic nerve sheath meningioma. Radiotherapy and Oncology, 2004, 72, 169-174.	0.3	106
53	Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer, 2003, 97, 1063-1071.	2.0	142
54	Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. Anti-Cancer Drugs, 2002, 13, 163-167.	0.7	20

#	Article	IF	CITATIONS
55	Importance of Radiotherapy in the Outcome of Patients With Primary CNS Lymphoma: An Analysis of the CHOD/BVAM Regimen Followed by Two Different Radiotherapy Treatments. Journal of Clinical Oncology, 2002, 20, 231-236.	0.8	144
56	Outcome and patterns of failure in testicular lymphoma: a multicenter rare cancer network study. International Journal of Radiation Oncology Biology Physics, 2002, 52, 652-656.	0.4	58
57	CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma. International Journal of Radiation Oncology Biology Physics, 2001, 50, 457-464.	0.4	84
58	Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. European Journal of Cancer, 1999, 35, 738-743.	1.3	157
59	Efficacy of radiotherapy for malignant gliomas in elderly patients. International Journal of Radiation Oncology Biology Physics, 1998, 42, 977-980.	0.4	64
60	Primary central nervous system lymphoma of T-cell origin: description of two cases and review of the literature. Journal of Neuro-Oncology, 1997, 34, 157-161.	1.4	41
61	Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy Journal of Clinical Oncology, 1996, 14, 945-954.	0.8	74
62	Levothyroxine suppressive therapy for solitary thyroid nodule. Journal of Endocrinological Investigation, 1995, 18, 796-799.	1.8	30
63	Induction chemotherapy with cisplatin, bleomycin and methotrexate in advanced head and neck cancer—lack of therapeutic gain. Radiotherapy and Oncology, 1987, 10, 175-181.	0.3	6